MedTrace Logo

Clinical Study on the Treatment of Type 1 Diabetes With CNK-UT009 Cell Injection

NCT07051564 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-07-04

No results posted yet for this study

Summary

This is a single-arm, open, investigator-initiated clinical study of CNK-UT009 cell injection in patients with type 1 diabetes. The purpose of this study is to evaluate the safety and tolerability of CNK-UT009 cell injection in patients with type 1 diabetes mellitus, determine the maximum tolerated dose (MTD), and evaluate the initial therapeutic effectiveness, PK characteristics and immunogenicity of CNK-UT009 cell injection. And the effect of CNK-UT009 cell injection on peripheral blood immune cells and serum cytokines.

Conditions

  • Type 1 Diabetes (T1D)

Interventions

BIOLOGICAL

CNK-UT009 cell injection

CNK-UT009 cell injection

Sponsors & Collaborators

  • Zibo Central Hospital

    lead OTHER_GOV

Principal Investigators

  • Xiaoming Pang, Doctor · Zibo Central Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-06
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07051564 on ClinicalTrials.gov